0001209191-14-030387.txt : 20140501
0001209191-14-030387.hdr.sgml : 20140501
20140501194420
ACCESSION NUMBER: 0001209191-14-030387
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140501
FILED AS OF DATE: 20140501
DATE AS OF CHANGE: 20140501
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15 NEW ENGLAND EXECUTIVE PARK
CITY: BURLINGTON
STATE: MA
ZIP: 01803
BUSINESS PHONE: 617-513-9882
MAIL ADDRESS:
STREET 1: 15 NEW ENGLAND EXECUTIVE PARK
CITY: BURLINGTON
STATE: MA
ZIP: 01803
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brady Todd C
CENTRAL INDEX KEY: 0001579179
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 14806606
MAIL ADDRESS:
STREET 1: C/O EVOKE PHARMA, INC.
STREET 2: 12555 HIGH BLUFF DR SUITE 385
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2014-05-01
0
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001579179
Brady Todd C
C/O ALDEYRA THERAPEUTICS, INC.
15 NEW ENGLAND EXECUTIVE PARK
BURLINGTON
MA
01803
1
1
0
0
President and CEO
Common Stock
2589
D
Employee Stock Option (Right to Buy)
0.552
2023-09-07
Common Stock
192084
D
Employee Stock Option (Right to Buy)
0.552
2023-09-07
Common Stock
32953
D
Employee Stock Option (Right to Buy)
0.552
2023-09-07
Common Stock
48021
D
Employee Stock Option (Right to Buy)
4.56
2023-10-29
Common Stock
96042
D
Exercisable over four years of service from April 15, 2013, with 25% vesting upon completion of 12 months of service and in 36 equal monthly installments thereafter.
This option became exercisable with respect to 1/6th of the shares each month over six months of continuous service following April 1, 2013.
Exercisable with respect to 16,007 shares upon each of the effective date of the initial public offering, the date on which the Issuer's closing market capitalization equals at least $55.0 million for 10 consecutive trading days and the date on which the Issuer's closing market capitalization equals at least $70.0 million for 10 consecutive trading days, provided that Dr. Brady remains in continuous service with the Issuer through each such date.
Exercisable with respect to 1/16th of the shares in quarterly installments over four years of continuous service following October 30, 2013.
/s/ Todd C. Brady
2014-05-01